Model-Based Meta-Analysis (MBMA) at GSK: Real-World Impact on Strategy and Trials
GSK shares real-world case studies on how Model-Based Meta-Analysis (MBMA) supports dose selection, virtual control…
CertaraJuly 31, 2025
Recapping a record-breaking 2025 Krakow HTA Symposium
We cover the key takeaways from CERTAINTY 2025, including the power of Model-Informed Drug Development…
Simona ColucciJuly 30, 2025
Optimizing Dosing and Regulatory Outcomes in Duchenne Muscular Dystrophy (DMD) Drug Development
Certara supported DMD drug development for Givinostat, helping Italfarmaco with pharmacometric and regulatory strategy.
CertaraJuly 29, 2025
